Shree Pacetronix Ltd. (SHREEPAC) — Tipsheet

Shree Pacetronix's joint MD just put ₹2.56 cr of his own money into the stock

Tipsheet Editorial — Wed, 10 Jun 2026 17:22:35 GMT

Akash Sethi's stake jumped from 8.76% to 13.51% after acquiring 1,78,000 shares in an off-market deal worth ~4.7% of the ₹54 crore company.

What’s new

Joint MD Akash Sethi acquired 1,78,000 shares via off-market transfer from Bio Pace Technology INC.
His voting stake increased from 8.76% to 13.51% of the cardiac-device maker's equity.
He already holds warrants convertible into another 1.50 lakh shares.

Why it matters

For a company worth ₹54 crore, deploying ₹2.56 crore of personal capital is a significant commitment from a senior insider. It directly increases the joint MD's alignment with minority shareholders and removes a block from the share register.

What we’re watching

Whether Sethi converts his outstanding warrants for another 1.50 lakh shares.
Any further stakebuilding by Sethi or other insiders.
Bio Pace Technology's remaining position after this off-market transfer.

The full read

Akash Sethi is the joint managing director of Shree Pacetronix, a ₹54 crore cardiac-device maker. He just bought 1,78,000 shares from Bio Pace Technology in an off-market deal valued at about ₹2.56 crore. That's nearly 4.7% of the company's entire market value deployed in one transaction. His direct stake jumped from 8.76% to 13.51%. A big move. He already holds warrants convertible into 1.50 lakh more shares, so his potential exposure is even higher. The seller, Bio Pace Technology, has cleanly exited a position. For a promoter already running the company, this is a clear, voluntary allocation of personal capital into the stock. The open question is whether this is a one-off or the beginning of a larger accumulation.

Primary source: BSE · NSE

Shree Pacetronix's profit surges 300% on leaner balance sheet

Tipsheet Editorial — Mon, 25 May 2026 19:52:33 GMT

Net profit jumped to ₹3.02 crore from ₹75.30 lakhs as borrowings fell and revenue grew 29%.

What’s new

Revenue grew 29% to ₹21.64 crore in FY26 from ₹16.80 crore.
Net profit surged ~300% to ₹3.02 crore from ₹75.30 lakhs.
Borrowings declined, lifting EPS to ₹8.31 from ₹2.09.

Why it matters

The profit surge outpaces revenue growth, which points to more than just higher sales. The combination of a cleaner balance sheet and lower finance costs is the real driver. This is the kind of de-leveraging that can make a small-cap's earnings cycle volatile.

What we’re watching

Whether the improved capital structure holds through FY27.
If the 29% revenue growth rate can be maintained.
How the company uses its stronger equity base.

The full read

Shree Pacetronix's FY26 results are a clear beat. Revenue climbed 29% to ₹21.64 crore. But profit exploded. Net income surged to ₹3.02 crore from ₹75.30 lakhs, a nearly 300% increase. EPS jumped to ₹8.31 from ₹2.09. The profit growth is not just scaling with sales. It is outstripping them. That gap comes from a lighter balance sheet; the company cut its borrowings, which lowered finance costs. For a company of this scale, that kind of de-leveraging is a material shift. The audit is clean. The next test is whether this marks a new baseline or a one-year base effect from a depressed prior year.

Primary source: BSE · NSE

Shree Pacetronix checks its annual boxes

Tipsheet Editorial — Mon, 25 May 2026 19:44:33 GMT

A routine board meeting approved the FY26 results, auditors, and related-party transactions. No figures were provided.

What’s new

Board approved audited results for Q4 and the full year ended March 31, 2026.
Appointed internal and statutory auditors.
Recommended related party transactions.

Why it matters

This is a procedural filing. The approval of annual results and auditors is a standard corporate requirement. For a nano-cap company, the filing carries no forward signal beyond confirming the books are signed.

What we’re watching

The actual financial numbers, which were not included in this filing.
Any management commentary on forward performance.

The full read

Shree Pacetronix's board met to tick the annual boxes. It approved the Q4 and FY26 audited results, appointed internal and statutory auditors, and recommended related party transactions. That's the filing. No numbers were disclosed. No guidance offered. For a nano-cap company, this is procedure, not news.

Primary source: BSE · NSE